Table 3.
Haploidentical transplant: comparison of graft source
| Bone marrow | Peripheral blood | P | |||
|---|---|---|---|---|---|
| Outcomes | N evaluable | Cumulative incidence (95% CI), % |
N evaluable | Cumulative incidence (95% CI), % |
|
| Day 100 grade II to IV acute GVHD | 126 | 21 (14-28) | 247 | 30 (25-26) | .04 |
| Day 100 grade III to IV acute GVHD | 119 | 6 (2-11) | 233 | 6 (4-10) | .84 |
| Chronic GVHD at 3 y | 124 | 22 (15-30) | 244 | 48 (41-56) | <.001 |
| Nonrelapse mortality at 3 y | 126 | 6 (2-10) | 247 | 14 (10-19) | .03 |
| Relapse at 3 y | 126 | 35 (26-45) | 247 | 35 (27-43) | .51 |
| Overall survival at 3 y | 126 | 71 (62-80) | 249 | 60 (52-68) | .39 |
| Leukemia-free survival at 3 y | 126 | 59 (49-69) | 247 | 51 (43-59) | .40 |